Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Addition of Belimumab to B-cell Depletion to Produce Prolonged Remission of Relapsing-remitting Multiple Sclerosis Disease Activity

NCT04767698 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT04767698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04767698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Addition of Belimumab to B-cell Depletion to Produce Prolonged Remission of Relapsing-remitting Multiple Sclerosis Disease Activity
Lead sponsor
Johns Hopkins University
Phase
Phase 2
Overall status
Terminated
Start date
October 1, 2021
Completion date
May 10, 2022
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis